Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized , Open-label, Multicenter, Phase II Study to Compare the Efficacy of S-1 and S-1 Plus Leucovorin as Second Line Treatment on Gemcitabine-refractory Patients With Inoperable or Advanced Pancreatic Cancers

NCT01074996 is registered in ClinicalTrials.gov with The Affiliated Hospital of the Chinese Academy of Military Medical Sciences as lead sponsor.

NCT NCT01074996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01074996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized , Open-label, Multicenter, Phase II Study to Compare the Efficacy of S-1 and S-1 Plus Leucovorin as Second Line Treatment on Gemcitabine-refractory Patients With Inoperable or Advanced Pancreatic Cancers
Lead sponsor
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase
Phase 2
Overall status
Unknown status
Start date
February 28, 2010
Completion date
July 31, 2014
Enrollment
92 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer